Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

Nature

Volumn 548, Issue 7666, 2017, Pages 234-238

  Yao, Zhan ^a   Yaeger, Rona ^a   Rodrik Outmezguine, Vanessa S ^a   Tao, Anthony ^b   Torres, Neilawattie M ^a   Chang, Matthew T ^a,c   Drosten, Matthias ^d   Zhao, Huiyong ^a   Cecchi, Fabiola ^e   Hembrough, Todd ^e   Michels, Judith ^f,g   Baumert, Hervé ^h   Miles, Linde ^a,i   Campbell, Naomi M ^a   De Stanchina, Elisa ^a   Solit, David B ^a   Barbacid, Mariano ^d   Taylor, Barry S ^a   Rosen, Neal ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Structural Biology and Biocomputing Programme   (Spain)

^e NantOmics   (United States)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h SAINT JOSEPH HOSPITAL   (France)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CETUXIMAB; HOMODIMER; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR FACTOR I; PROTEIN TYROSINE KINASE; RAS PROTEIN; TRAMETINIB; VEMURAFENIB; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN P21; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; SULFONAMIDE;

ALLELE; CANCER; CHEMICAL BINDING; ENZYME ACTIVITY; INHIBITION; MUTATION; SENSITIVITY ANALYSIS; TUMOR;

ANIMAL CELL; ARTICLE; CANCER RESEARCH; DIMERIZATION; INTRACELLULAR SIGNALING; MELANOMA; MELANOMA CELL LINE; MOUSE; MUTANT; MUTATION; NEGATIVE FEEDBACK; NIH 3T3 CELL LINE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TUMOR REGRESSION; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; MAPK SIGNALING; METABOLISM; NEUROFIBROMATOSIS TYPE 1; PROTEIN MULTIMERIZATION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; INDOLES; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; NEUROFIBROMATOSIS 1; NIH 3T3 CELLS; ONCOGENE PROTEIN P21(RAS); PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85027337895     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature23291     Document Type: Article

References (18)

1. Yao, Z. et al. BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. Cancer Cell 28, 370-383 (2015).
2. Wan, P. T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004).
3. Drosten, M. et al. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J. 29, 1091-1104 (2010).
4. Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
5. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161, 1681-1696 (2015).
6. Chang, M. T. et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat. Biotechnol. 34, 155-163 (2016).
7. Hall, R. D. & Kudchadkar, R. R. BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies. Cancer Contr. 21, 221-230 (2014).
8. Zheng, G. et al. Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. BMC Cancer 15, 779 (2015).
9. Nieto, P. et al. A Braf kinase-inactive mutant induces lung adenocarcinoma. Nature http://dx.doi.org/10.1038/nature23297 (2017).
10. Chen, S. H. et al. Oncogenic BRAF deletions that function as homodimers and are sensitive to inhibition by RAF dimer inhibitor LY3009120. Cancer Discov. 6, 300-315 (2016).
11. Garnett, M. J., Rana, S., Paterson, H., Barford, D. & Marais, R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20, 963-969 (2005).
12. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
13. Karoulia, Z. et al. An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling. Cancer Cell 30, 485-498 (2016).
14. Poulikakos, P. I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390 (2011).
15. Yang, H. et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70, 5518-5527 (2010).
16. Cheng, D. T. et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. JMD 17, 251-264 (2015).
17. Hembrough, T. et al. Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffinembedded tumor tissue. JMD 15, 454-465 (2013).
18. Catenacci, D. V. et al. Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PLoS One 9, e100586 (2014).